AMPLIFY study shows Duaklir significantly improves lung function in COPD

7 September 2017

New data show that Duaklir achieved the primary endpoints according to the AMPLIFY data, which will be valuable to support a New Drug Application submission to the US Food and Drug Administration.

Spain’s largest drugmaker Almirall (ALM: MC) has announced positive top-line Phase III results, which shows that Duaklir (aclidinium bromide/formoterol 400µg/12µg twice-daily) met the primary endpoints in the AMPLIFY high-level read-out, demonstrating a statistically-significant and clinically-relevant improvement in lung function in moderate to very severe stable chronic obstructive pulmonary disease (COPD) patients compared to each individual component (either aclidinium bromide or formoterol).

The drug is licensed to Anglo-Swedish pharma major AstraZeneca’s (LSE: AZN) in Europe, where it gained approval for the treatment of COPD in November 2014.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK